Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study

Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study

Background: Monoclonal antibodies (mAbs) against calcitonin gene-related peptides (CGRP) are novel treatments for migraine prevention. Based on a previous functional imaging study which investigated the CGRP receptor mAb (erenumab), we hypothesized that (i) the CGRP ligand mAb galcanezumab would alt...

Full description

Bibliographic Details
Main Authors: Hauke Basedau, Lisa-Marie Sturm, Jan Mehnert, Kuan-Po Peng, Marlene Schellong, Arne May
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2022-05-01
Series:eLife
Subjects:
migraine
medication
CGRP antibodies
functional imaging
pathophysiology
hypothalamus
Online Access:https://elifesciences.org/articles/77146

Internet

https://elifesciences.org/articles/77146

Similar Items